…
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -3.61M | -5.35M | -7.26M | -5.78M | -4.87M |
| Minority interest | 0.15M | 0.15M | 0.74M | 0.04M | 0.04M |
| Net income | -4.00M | -5.19M | -6.52M | -5.74M | -4.82M |
| Selling general administrative | 5.11M | 3.99M | 5.80M | 5.28M | 4.21M |
| Gross profit | -0.08M | 0.03M | 0.19M | 0.21M | 0.24M |
| Reconciled depreciation | 0.07M | 0.02M | 0.02M | 0.05M | 0.06M |
| Ebit | -3.50M | -4.05M | -7.30M | -5.71M | -4.54M |
| Ebitda | -3.42M | -4.03M | -7.28M | -5.66M | -4.48M |
| Depreciation and amortization | 0.08M | 0.02M | 0.02M | 0.05M | 0.06M |
| Operating income | -4.23M | -4.05M | -7.30M | -5.71M | -4.54M |
| Other operating expenses | 4.23M | 4.26M | 7.56M | 6.10M | 4.98M |
| Interest expense | 0.11M | 0.10M | 0.01M | 0.01M | 0.04M |
| Tax provision | -0.02M | 0.00M | - | - | - |
| Interest income | - | 0.07M | 0.07M | 0.03M | - |
| Net interest income | -1.63M | -0.12M | 0.06M | 0.02M | -0.15M |
| Income tax expense | -0.02M | - | - | - | - |
| Total revenue | 0.00M | 0.21M | 0.26M | 0.39M | 0.44M |
| Total operating expenses | 4.23M | 4.08M | 7.49M | 5.92M | 4.79M |
| Cost of revenue | 0.08M | 0.18M | 0.08M | 0.19M | 0.19M |
| Total other income expense net | 0.62M | -1.30M | 0.04M | -0.07M | -0.32M |
| Net income from continuing ops | -3.60M | -5.35M | -7.26M | -5.78M | -4.87M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 20.41M | 5.46M | 7.24M | 6.49M | 7.60M |
| Intangible assets | 5.15M | - | - | - | - |
| Other current assets | 1.41M | 0.49M | 0.76M | 0.25M | 0.23M |
| Total liab | 4.67M | 0.89M | 0.79M | 0.75M | 1.18M |
| Total stockholder equity | 16.01M | 4.75M | 6.48M | 5.85M | 6.48M |
| Other current liab | 0.68M | 0.84M | 0.69M | 0.23M | 0.34M |
| Common stock | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -38.56M | -34.55M | -29.36M | -22.84M | -17.10M |
| Good will | 6.29M | 0.00M | - | - | - |
| Cash | 3.83M | 2.21M | 4.48M | 5.75M | 6.81M |
| Total current liabilities | 1.43M | 0.89M | 0.78M | 0.71M | 0.93M |
| Net debt | -2.84M | -2.20M | -4.42M | -5.60M | -6.58M |
| Short term debt | 0.75M | 0.01M | 0.04M | 0.07M | 0.05M |
| Short long term debt | 0.74M | - | - | - | 0.01M |
| Short long term debt total | 0.99M | 0.01M | 0.05M | 0.15M | 0.23M |
| Other stockholder equity | 54.60M | 39.33M | 35.87M | 28.71M | 23.61M |
| Total current assets | 6.01M | 3.40M | 5.47M | 6.27M | 7.23M |
| Long term investments | 2.74M | 1.41M | 1.66M | 0.00M | - |
| Short term investments | 0.24M | 0.31M | 0.00M | - | - |
| Net receivables | 0.53M | 0.38M | 0.11M | 0.19M | 0.17M |
| Long term debt | 0.24M | - | - | - | - |
| Inventory | - | 0.02M | 0.12M | 0.08M | 0.02M |
| Accounts payable | 0.01M | 0.05M | 0.04M | 0.42M | 0.54M |
| Accumulated other comprehensive income | -0.04M | -0.03M | -0.03M | -0.03M | -0.03M |
| Non currrent assets other | 0.16M | 0.24M | - | - | 0.14M |
| Non current assets total | 14.39M | 2.06M | 1.78M | 0.22M | 0.37M |
| Capital lease obligations | 0.01M | 0.01M | 0.05M | 0.11M | 0.13M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -0.22M | 0.00M | - | - |
| Total cashflows from investing activities | -3.23M | -1.89M | -1.52M | -0.05M | -0.08M |
| Net borrowings | 1.38M | -0.09M | 0.00M | -0.01M | 0.23M |
| Total cash from financing activities | 8.86M | 3.05M | 3.47M | 4.09M | 10.73M |
| Net income | -4.16M | -5.19M | -6.52M | -5.74M | -4.82M |
| Change in cash | 1.80M | -2.27M | -1.27M | -1.06M | 6.54M |
| Begin period cash flow | 2.21M | 4.48M | 5.75M | 6.81M | 0.27M |
| End period cash flow | 4.01M | 2.21M | 4.48M | 5.75M | 6.81M |
| Total cash from operating activities | -3.81M | -3.42M | -3.23M | -5.10M | -4.10M |
| Issuance of capital stock | 1.50M | 0.00M | 0.00M | 4.10M | 10.50M |
| Depreciation | 0.07M | 0.02M | 0.02M | 0.05M | 0.06M |
| Other cashflows from investing activities | -0.87M | -0.66M | - | - | -0.02M |
| Change to inventory | 0.01M | 0.10M | -0.04M | -0.06M | -0.01M |
| Change to account receivables | 0.01M | -0.04M | 0.09M | -0.02M | -0.02M |
| Other cashflows from financing activities | 4.15M | 3.13M | 3.47M | - | -0.04M |
| Capital expenditures | 0.01M | 0.00M | 0.00M | 0.05M | 0.07M |
| Change in working capital | -0.10M | 0.17M | 0.29M | -0.27M | -0.05M |
| Stock based compensation | 2.15M | 0.75M | 2.50M | 0.94M | 0.64M |
| Other non cash items | -1.77M | 1.59M | 2.98M | 0.86M | 0.72M |
| Free cash flow | -3.82M | -3.42M | -3.23M | -5.15M | -4.17M |
Sector: Basic Materials Industry: Agricultural Inputs
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NXTS Nexentis Technologies Inc. |
-0.13 5.23% |
2.44 | 0.19 | - | 4.32 | 1.19 | 5.81 | 0.28 |
| CTA-PB E. I. du Pont de Nemours and Company |
- -% |
56.50 | - | - | 3.43 | - | - | - |
| CTVA Corteva Inc |
0.10 0.80% |
11.99 | 49.93 | 19.65 | 3.12 | 2.19 | 3.23 | 19.19 |
| CTA-PA E. I. du Pont de Nemours and Company |
-0.96 2.08% |
45.04 | - | - | 2.71 | - | - | - |
| NTR Nutrien Ltd |
0.64 0.90% |
72.12 | 15.94 | 14.90 | 1.38 | 1.42 | 1.72 | 7.72 |
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
| Name | Title | Year Born |
|---|---|---|
| Mr. David Palach | Chief Executive Officer | 1966 |
| Ms. Lital Barda | CFO, Financial Controller, Treasurer & Secretary | 1987 |
| Ms. Galit Kenigsberg | Head of Sustainability Operations of scientific advisory board | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.